MYPOS
23.7.2020 15:54:07 CEST | Business Wire | Press release
The European company, myPOS, specialised in offering affordable payments technology to SMEs, has launched a new series of premium cards for its customers: the myPOS Visa Platinum Metal Card and myPOS Visa Platinum Silver & Gold Card. The offering includes a range of benefits such as a LoungeKey pass to over 1000 airport business lounges worldwide, 0.1% cashback on all purchases, 10 or 15% cashback for every purchase in the myPOS online shop and myPOS physical stores in Europe, free ATM withdrawals on a monthly basis, free delivery and reissuing and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200723005575/en/
Christo Georgiev, myPOS Founder, said: “Currently, the Metal cards are available for individual clients only. Together with Visa, we are pioneering this space by offering the first metal card for businesses in Europe.”
The myPOS Visa Platinum Silver, Gold and Metal cards will be offered in Europe to all merchants using the myPOS platform for a monthly or annual subscription and will be in addition to myPOS’ current business card. The metal Platinum Visa card will be offered to micro and small merchants – this distinguishes the myPOS offering in Europe where prestigious metal cards are typically offered mainly to individual consumers.
While the Visa Platinum card is available in two designs – Gold and Silver, the exclusive Visa Metal card comes in brushed black metal with laser engraving and is three-times the weight of a standard card. Its metal coating keeps it protected, so it won’t get warped, cracked or damaged.
Through the new Visa Platinum cards, myPOS is enabling micro and small merchants to access premium services that they may not have previously been able to receive.
Since its official introduction in 2014, myPOS has been offering a free business card with every myPOS account as part of its unique payment acceptance solution with instant pay-out of the received funds.
About myPOS
myPOS is a fintech company serving over 100,000 business clients across the European Economic Area. The myPOS e-money accounts and payment services are provided by myPOS Europe, a UK E-Money Institution, authorised and regulated by the FCA in partnership with an EU-licensed E-Money Institution, a direct member of Visa, Mastercard, Amex, JCB, UPI and other card schemes.
myPOS was awarded the Best POS Innovation by the Merchant Payments Ecosystem in 2019 and Best B2B payments company by the Breakthrough Awards program in 2020.
myPOS headquarters are located at Level 24, The Shard, London Bridge Street, London SE1 9SG, UK.
Find out more on www.myPOS.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005575/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom